143rd iCeMS Seminar: Dr. Tsuneaki Sakata, Dr. Sotirios Karathanasis, Dr. Stephen Minger

Dr. Tsuneaki Sakata

Shionogi Science Program: an industry-academic initiative for open innovation in pharmaceutical industry

Shionogi has a long history of building partnerships and collaborating with researchers in areas of interest and unmet medical need. As part of this wider goal, the Shionogi Science Program (SSP) was launched in the UK in 2011 following the success of the Japanese initiative FINDS (PHarma-INnovation Discovery competition Shionogi) which was founded in 2007.

Dr. Sotirios Karathanasis

Industry-Academia Collaborations: Current Trends and Issues to Overcome

Although a variety of factors contribute to the productivity decline of the Pharmaceutical Industry (Pharma) in recent years, the declining ability to innovate is thought to play a fundamental role. This, so called "innovation deficit", occurs in the background of an accelerated pace of innovation in Academia. Dr. Karathanasis will discuss possible factors responsible for this "innovation deficit" in Pharma, focusing on elements that might prevent Academic innovations from effective translocation, internalization, and translation into new drug Discovery and Development projects in Pharma. Finally, he will overview current models for Industry-Academia collaborations and discuss issues to overcome.


Dr. Stephen Minger

Innovating Preclinical Drug Development & Human Cell Therapy

The isolation of tissue-specific, multipotent stem cells from adult organs and the derivation of pluripotent human embryonic stem cells offer the potential for regeneration of a number of different tissues and organs susceptible to age-related degenerative conditions and traumatic injury. In the not-too-distant future, it will be possible to repair heart tissue damaged by myocardial infarction, to replace neuronal cells lost in Parkinson's and Alzheimer's diseases, to transplant new insulin producing cells for diabetics and myelinating cells for individuals afflicted with multiple sclerosis, and to replace bone and cartilage lost through aging and inflammatory disease.

Lecturer Dr. Tsuneaki Sakata
Head, Innovation Design Office, Global Development, Shionogi & Co., Ltd.

Dr. Sotirios Karathanasis
Executive Director, Strategy and Externalization Cardiovascular and Gastrointestinal Research Area AstraZeneca

Dr. Stephen Minger
Chief Scientist, Cellular Sciences, Life Sciences, GE Healthcare
Date / Time October 24, 2013 / 10:00-12:00
Venue 2nd floor Seminar Room (#A207), iCeMS Main Building, Kyoto University
Directions
Flyer PDF FilePDF (185KB)
Host Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University
Co-Host NPO Kyoto SMI
Registration Required. Register by Tusday 15 October at the Kyoto SMI website
Contact Takashi Asada | tasada@icems.kyoto-u.ac.jp